Loading...

Intra-Cellular Therapies, Inc.

ITCINASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$131.87
$0.00(0.00%)

Intra-Cellular Therapies, Inc. (ITCI) Stock Competitors & Peer Comparison

See (ITCI) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ITCI$131.87+0.00%14B-180.64-$0.73N/A
ZTS$152.12-0.46%67.7B27.34$5.56+1.27%
TAK$14.48-1.19%45.7B62.91$0.23+4.07%
HLN$9.88+0.30%44.4B23.52$0.42+1.71%
TEVA$16.54+1.29%19B-14.39-$1.15N/A
NBIX$132.14+0.38%13.1B44.81$2.95N/A
RDY$14.67-0.27%12.2B18.56$0.79+0.50%
CTLT$63.48+0.00%11.5B-27.84-$2.28N/A
VTRS$9.41+0.64%11B-2.96-$3.18+5.12%
RGC$15.05-0.86%7.4B-1505.00-$0.01N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ITCI vs ZTS Comparison July 2025

ITCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITCI stands at 14B. In comparison, ZTS has a market cap of 67.7B. Regarding current trading prices, ITCI is priced at $131.87, while ZTS trades at $152.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITCI currently has a P/E ratio of -180.64, whereas ZTS's P/E ratio is 27.34. In terms of profitability, ITCI's ROE is -0.07%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, ITCI is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for ITCI.Check ZTS's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;